throbber
Page 1
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`WATSON LABORATORIES,
`
`INC.,
`
`Petitioner,
`
`vs.
`
`UNITED THERAPEUTICS CORP.,
`
`Patent Owner.
`
`)
`
`)
`
`)
`
`)
`
`)
`
`IPR NO. 2017-01621
`
`IPR NO. 2017-01622
`
`The videotaped deposition of MAUREEN
`
`DONOVAN, Ph.D., called as a witness for
`
`examination,
`
`taken pursuant to the Federal
`
`Rules of Civil Procedure of the United States
`
`District Courts pertaining to the taking of
`
`depositions,
`
`taken before ANDREA L. KIM, a
`
`Certified Shorthand Reporter of said state, CSR
`
`No. 84-3722, at Suite 4800, 35 West Wacker
`
`Drive, Chicago, Illinois, on the 4th day of
`
`April, A.D. 2018, at 9:37 a.m.
`
`Job No: 54284
`
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 1 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`

`

`Page 2
`
`PRESENT:
`
`WINSTON & STRAWN, LLP
`
`35 West Wacker Drive
`
`Chicago, Illinois 60601
`
`S12-558-8329
`
`BY: KURT A. MATHAS, ESQ.
`
`kmathas@winston.com
`
`appeared on behalf of the Petitioner;
`
`
`
`WILSON SONSINI GOODRICH & ROSATI
`
`1700 K Street, NW, Fifth Floor
`
`Washington, DC 20006-3817
`
`202-973-8812
`
`BY: VERONICA S. ASCARRUNZ, ESQ.
`
`vascarrunz@wsgr.com
`
`-and-
`
`FOLEY & LARDNER, LLP
`
`3000 K Street, N.W., Suite 600
`
`Washington, D.C. 20007
`
`202-672-5569
`
`BY: STEPHEN B. MAEBIUS, ESQ.
`
`smaebius@foley.com
`
`NATASHA IYER, ESQ.
`
`niyer@foley.com
`
`appeared on behalf of Patent Owner;
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 2 of 201
`
`&WwNOF
`oawowo
`
`10
`
`14
`
`12
`
`Ls
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`

`

`
`
`Page 3
`
`ALSO PRESENT:
`
`MR.
`
`JEREMY MANGAN, Videographer.
`
`
`
`REPORTED BY:
`
`ANDREA L. KIM,
`
`Illinois CSR No. 84-3722.
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIESv. UNITED THERAPEUTICS, IPR2017-01622
`Page 3 of 201
`
`&WwNOF
`oaoOwo
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`

`

`INDEX
`
`Page 4
`
`PAGE:
`
`MAUREEN DONOVAN, Ph.D.
`
`EXAM by MS.
`
`ASCARRUNZG..............
`
`6
`
`EXAM by MR.
`
`MATHAS..... 2.2.22 eee eee ee
`
`158
`
` WITNESS:
`
`kkekkk
`
`tHDE &
`
`EXHIBIT NUMBER
`
`MARKED
`
`Bh DOO8 2
`
`saw eu wus
`
`Br SWE ee we ee ee ee ec ee eee
`
`13
`
`Bxzhibit L001: w ss
`
`eee 13
`
`Exh TOQ02 «aces wevs
`
`2 WIM ee ee ew tc ee wt ce eee 8
`
`Exhibit 1002....
`
`we eee ee ee ee ee eee
`
`9
`
`Exhibit 1003564.
`
`TTTCT 46
`
`Exhibit 1004....
`
`Hon MM ee ee tc ee et ee ee ee 46
`
`Exhibit L005...
`
`ee 47]
`
`Exhibit LOL2:.....
`
`ee 48
`
`Exhibit 1046....
`
`te ee ee ee ee ee ee eee 86
`
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 4 of 201
`
`&WwNOF
`oa1oOwo
`
`10
`
`14
`
`12
`
`Ls
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`

`

`Page 5
`
`MAUREEN DONOVAN, Ph.D.
`
`THE VIDEOGRAPHER: We are now on
`
`
`
`the record. This marks the beginning of media
`
`number 1
`
`in the deposition of Maureen Donovan
`
`in the matter of Watson Laboratories, Inc.,
`
`versus United Therapeutics Corporation in the
`
`U.S. District Court, District of New Jersey.
`
`This deposition is being held at 35
`
`West Wacker Drive, Chicago, Illinois on April
`
`4th, 2018, and the time is now 9:41 a.m.
`
`Will attorneys please identify
`
`themselves.
`
`MR. MATHAS: Good morning. Kurt
`
`Mathas from Winston & Strawn on behalf of the
`
`petitioner Watson Pharmaceuticals, Inc., and
`
`the witness Dr. Donovan, and for the record,
`
`I
`
`would note that the caption read on was the
`
`district court caption. We are actually here
`
`today in proceedings in two IPRs,
`
`IPR No.
`
`2017-1621 and 1622 titled Watson Laboratories,
`
`Inc., v. United Therapeutics Corp.
`
`MS. ASCARRUNZ: Good morning. My
`
`name is Veronica Ascarrunz from the law firm
`
`Wilson Sonsini Goodrich & Rosati
`
`in Washington,
`
`D.C. here representing the patent owner. With
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 5 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 6
`
`MAUREEN DONOVAN, Ph.D.
`
`me are co-counsel Stephen Maebius and Natash
`
`Iyer of Foley & Lardner in Washington, D.C.
`
`also representing the patent owner.
`
`THE VIDEOGRAPHER: Will
`
`the court
`
`reporter please swear in the witness.
`
`(WHEREUPON,
`
`the witness was duly
`
`sworn.)
`
`MAUREEN DONOVAN, Ph.D.,
`
`called as a witness herein, having been first
`
`duly sworn, was examined and testified as
`
`follows:
`
`BY MS. ASCARRUNZ:
`
`EXAMINATION
`
`
`
`Q.
`
`A.
`
`Q.
`
`Good morning, Dr. Donovan.
`
`Good morning.
`
`Could I get you to state your
`
`full name for the record, please.
`
`A.
`
`C:.
`
`Maureen Donovan.
`
`And you have been deposed
`
`before, correct?
`
`A.
`
`Q
`
`Yes,
`
`I have.
`
`Approximately how many times?
`
`A.
`
`About 11 times.
`
`Have you been deposed in an
`Q
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 6 of 201
`
`&WwNOF
`oa1oOwo
`
`10
`
`14
`
`12
`
`Ls
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`

`

`Page 7
`
`MAUREEN DONOVAN, Ph.D.
`
`IPR proceeding before?
`
`A.
`
`Q.
`
`Yes,
`
`I have.
`
`And,
`
`therefore,
`
`I -- I know
`
`you understand the ground rules.
`
`I'm going to
`
`go over just a few of the most important ones
`
`to make sure we are on the same page.
`
`You understand that you are
`
`here today to testify truthfully because you
`
`are under oath just as if you were ina
`
`courtroom or in front of the Board?
`
`A.
`
`QO.
`
`Yes.
`
`And because we have a court
`
`reporter taking down our questions and answers,
`
`I would ask that you wait until I finish asking
`
`my question before you begin to answer.
`
`
`
`A.
`
`Q.
`
`Is that fair?
`
`Yes.
`
`And if you don't understand
`
`one of my questions, will you please let me
`
`know?
`
`A.
`
`Okay.
`
`Otherwise, if you answer my
`
`question,
`
`I will assume that you understood it.
`
`Is that fair?
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 7 of 201
`
`&WwNOF
`oa1oOwo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 8
`
`MAUREEN DONOVAN, Ph.D.
`
`Yes.
`
`We will probably take a few
`
`A.
`
`Q.
`
`
`
`breaks about on the hour or a little bit longer
`
`than an hour.
`
`If you need to take a break any
`
`time before I call for one, please just let me
`
`know.
`
`A.
`
`0:
`
`Okay.
`
`The only thing I will ask is
`
`if there's a question pending, let's answer the
`
`question first, and then we can take a break.
`
`A.
`
`QO.
`
`Sure.
`
`Are you aware of anything that
`
`prevent you from providing complete and
`
`truthful answers today?
`
`A.
`
`Q.
`
`No.
`
`I will start by handing you
`
`the first exhibit which is marked Exhibit 1002
`
`in case IPR 2017-01622.
`
`(WHEREUPON, a certain document
`
`was marked Deposition Exhibit
`
`1002, for identification,
`
`as of 4/4/18.)
`
`BY MS. ASCARRUNZ:
`
`is this a copy of
`Dr. Donovan,
`Q..
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 8 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 9
`
`MAUREEN DONOVAN, Ph.D.
`
`your expert declaration provided in case IPR
`
`2017-01622 in connection with Patent No.
`
`9,339,,5077
`
`A.
`
`Q.
`
`It appears to be, yes.
`
`And does this declaration bear
`
`your signature on page 105 of 105?
`
`A.
`
`Yes, it does.
`
`
`
`(WHEREUPON, a certain document
`
`was marked Deposition Exhibit
`
`1002, for identification,
`
`as of 4/4/18.)
`
`BY MS. ASCARRUNZ:
`
`Q.
`
`And for the record,
`
`the court
`
`reporter has just handed you Exhibit 1002 in
`
`IPR proceeding 2017-01621.
`
`Dr. Donovan,
`
`is this exhibit
`
`your expert declaration provided in case IPR
`
`2017-01621 in connection with Patent No.
`
`9,358,240?
`
`A.
`
`O.
`
`It appears to be, yes.
`
`And does this bear your
`
`signature on page 91 of 91?
`
`A.
`
`Yes, it does.
`
`So I notice that the two
`Q.
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 9 of 201
`
`&WwNOF
`oa1oOwo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 10
`
`MAUREEN DONOVAN, Ph.D.
`
`declarations have obviously different page
`
`numbers.
`
`I understand that there are also a
`
`number of other differences between the two
`
`declarations?
`
`yes.
`
`A.
`
`Q.
`
`There's several differences,
`
`Okay.
`
`One of the major
`
`
`
`differences is that you rely on the Chaudry
`
`reference in connection with the '507 patent,
`
`but not
`
`the '240 patent, correct?
`
`Pe
`
`I believe that's correct, yes.
`
`I could double check, but that's correct.
`
`Q.
`
`Okay.
`
`Since the '507 patent
`
`declaration contains additional pages and the
`
`discussion of Chaudry,
`
`is it fair to
`
`characterize that declaration as containing
`
`more information than is provided in the '240
`
`declaration?
`
`A.
`
`Well,
`
`the declaration for the
`
`'507 addresses issues that aren't pertinent to
`
`the '240.
`
`So it contains additional
`
`information.
`
`Q.
`
`Okay. Apart from those
`
`differences and additional sort of differences
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 10 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 11
`
`MAUREEN DONOVAN, Ph.D.
`
`in wording, et cetera,
`
`that are found between
`
`the two,
`
`is your opinion between the '240
`
`declaration and the '507 declaration
`
`consistent?
`
`
`
`MR. MATHAS: Object to the form.
`
`BY THE WITNESS:
`
`A.
`
`I guess there's a number of
`
`items in each of these reports that I express
`
`an opinion about.
`
`So I
`
`think it probably would
`
`be most helpful to step through each one of
`
`those individual items and describe whether my
`
`opinion is consistent or not.
`
`BY MS. ASCARRUNZ:
`
`Q.
`
`Okay. And we will. Where I
`
`am trying to go here is I don't want to ask you
`
`seven hours of questions on one and then seven
`
`hours of questions on the other.
`
`I would like
`
`to be able to use your testimony today to
`
`encompass both declarations, and where the
`
`differences are important, we can articulate
`
`those. Either I will do so in my question or
`
`if you feel the need to do so, you would do so
`
`as well.
`
`So that's the context of sort
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 11 of 201
`
`&WwNOF
`oa1oOwo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 12
`
`MAUREEN DONOVAN, Ph.D.
`
`of where I am going with this.
`
`I am not trying
`
`to do like sort of a gotcha of, you know,
`
`equating the two together.
`
`So is it fair to characterize
`
`the two declarations as being related?
`
`A.
`
`Q.
`
`Yes.
`
`Okay. And as having some
`
`degree of overlap?
`
`A:
`
`Yes,
`
`they is speak to many of
`
`the same issues.
`
`Q.
`
`Perfect. Okay.
`
`MS. ASCARRUNZ:
`
`So Kurt with that
`
`context and background, can we agree that this
`
`transcript will be used in both proceedings?
`
`MR. MATHAS: We can agree that the
`
`transcript will be used in both proceedings,
`
`
`
`yes.
`
`BY MS. ASCARRUNZ:
`
`Q.
`
`And as I said, Dr. Donovan,
`
`where I -- where my questions are specific to
`
`one patent or the other,
`
`I will try to make
`
`that clear, and I would ask that you do the
`
`same.
`
`If your opinion would different
`
`depending on which patent we are talking about,
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 12 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 13
`
`MAUREEN DONOVAN, Ph.D.
`
`please let me know.
`
`A.
`
`Q.
`
`Okay.
`
`So that you have them in front
`
`of you should you need them during the
`
`deposition,
`
`I will go ahead and give you the
`
`patents now.
`
`
`
`(WHEREUPON, certain documents
`
`was marked Deposition
`
`Exhibit 1001, 1001, for
`
`identification, as of 4/4/18.)
`
`BY MS. ASCARRUNZ:
`
`Q.
`
`So, Dr. Donovan,
`
`the court
`
`reporter has now handed you two exhibits.
`
`For
`
`the record, one is marked Exhibit 1001 in IPR
`
`proceeding 01622, and the other is also Exhibit
`
`1001 in IPR proceeding 01621.
`
`Do you have those in front of
`
`you?
`
`A.
`
`I have things that are marked
`
`one and two.
`
`Q.
`
`A.
`
`Q.
`
`Okay.
`
`So --
`
`If that's adequate,
`
`then, yes.
`
`Okay.
`
`The two items at the
`
`the two patents, both
`top of your table there,
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 13 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 14
`
`MAUREEN DONOVAN, Ph.D.
`
`of which are Exhibits 1001. Are those the two
`
`patents that are at issue in your declaration?
`
`A.
`
`Oh,
`
`I see what you mean by
`
`exhibit number.
`
`the -- the bottom numbers are listed as 1001.
`
`Actually, both of them are at
`
`
`
`Q.
`
`A.
`
`Q.
`
`Correct.
`
`Okay.
`
`And you will notice -- thank
`
`you for the clarification there. Les
`
`important
`
`to note at the bottom in the dark
`
`bold is the exhibit number as well as the
`
`proceeding and the page number.
`
`So when I
`
`am referring to page
`
`numbers, I'll typically refer to those.
`
`A
`
`i
`
`Okay.
`
`So you noted that they were
`
`both marked Exhibit 1001, correct?
`
`A.
`
`Q.
`
`That's correct.
`
`And you will notice that one
`
`is in connection with one of the proceedings,
`
`and one is in connection with the second
`
`proceeding. That's the distinction.
`
`Yes. Okay.
`A.
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 14 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`MAUREEN DONOVAN, Ph.D.
`
`Q.
`
`You are familiar with these
`
`Page 15
`
`patents, correct?
`
`
`
`Re
`
`Q..
`
`Yes,
`
`I am.
`
`Treprostinil is a component in
`
`all of the claims of those two patents,
`
`correct?
`
`A.
`
`Well,
`
`in the '507 treprostinil
`
`is mentioned in claim 1 and in claim 2, and all
`
`the rest of the claims are either dependent on
`
`one,
`
`two, or six, and six is dependent on two.
`
`So it's mentioned -- treprostinil is mentioned
`
`or dependent in all of the claims of the '507.
`
`And similarly for the '240,
`
`treprostinil is
`
`mentioned in claims 1 and 2 -- or actually
`
`claim 1. None of the other claims are
`
`dependent on claim 1, and for claim 2 and claim
`
`6,
`
`treprostinil is also mentioned in those.
`
`Q.
`
`Okay.
`
`You are using the word
`
`mentioned.
`
`Is treprostinil a limitation of all
`
`of the claims?
`
`Bic
`
`I think you would have to
`
`explain to me what you mean by a limitation in
`
`a claim.
`
`Q.
`Do you not have an independent
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 15 of 201
`
`&WwNOF
`oa1oOwo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 16
`
`MAUREEN DONOVAN, Ph.D.
`
`understanding of what a limitation in a patent
`
`claim is?
`
`A.
`
`I don't keep track of legal
`
`requirements for terminologies.
`
`I have looked
`
`at others to instruct me how to use those terms
`
`when necessary.
`
`Q.
`
`Okay. Fair enough. We can
`
`move on.
`
`You recall that I deposed you
`
`in this building in June of last year in
`
`connection with the district court action
`
`between the same parties involved in this
`
`proceeding, correct?
`
`A.
`
`Q.
`
`Yes.
`
`And your testimony in that
`
`other case included, among others, discussion
`
`about
`
`the same two patents that you have in
`
`front of you as Exhibits 1001, correct?
`
`
`
`A.
`
`Q.
`
`Correct.
`
`And at the time of that
`
`deposition, you were under oath and endeavored
`
`to answer my questions truthfully, correct?
`
`A.
`
`Yes.
`
`Have you reviewed that
`Q.
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 16 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 17
`
`MAUREEN DONOVAN, Ph.D.
`
`deposition testimony in connection with your
`
`work on this IPR?
`
`A.
`
`Q..
`
`I have.
`
`When was the last time you
`
`reviewed your deposition testimony?
`
`A.
`
`Q.
`
`Yesterday.
`
`And we previously talked about
`
`some of your expertise at that deposition.
`
`So
`
`I wouldn't rehash all of it today, but there
`
`are some issues that are probably important
`
`to
`
`discuss for these proceedings.
`
`You are an expert in
`
`Pharmaceutics, correct?
`
`A.
`
`Q.
`
`Yes.
`
`But you don't claim to be an
`
`expert in the law, correct?
`
`A.
`
`Q.
`
`No,
`
`I do not.
`
`And you are not a medical
`
`doctor, correct?
`
`
`
`A.
`
`0.
`
`No,
`
`I
`
`am not.
`
`And you do not claim to be an
`
`expert in the treatment of pulmonary
`
`hypertension, correct?
`
`No.
`A.
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 17 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 18
`
`MAUREEN DONOVAN, Ph.D.
`
`Q.
`
`And you have not researched
`
`pulmonary hypertension in your professional
`
`experience outside of this and the prior case
`
`between the parties, correct?
`
`A.
`
`Q..
`
`Not to any significant extent.
`
`Have you researched pulmonary
`
`hypertension in your professional experience to
`
`any extent?
`
`A:
`
`I was -- both in my
`
`professional and my personal experiences,
`
`I am
`
`familiar with pulmonary hypertension and have
`
`looked at treatments and disease state
`
`
`
`progression information.
`
`Q.
`
`Okay.
`
`You have not been
`
`involved in any clinical trials related to
`
`pulmonary hypertension, correct?
`
`A.
`
`Q.
`
`That's correct.
`
`And before the district court
`
`case between the parties, you were not familiar
`
`with TYVASO, correct?
`
`A.
`
`Q.
`
`Not
`
`to any extent, no.
`
`And before your involvement
`
`in
`
`the district court case between the parties,
`
`you were not familiar with treprostinil in any
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 18 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 19
`
`MAUREEN DONOVAN, Ph.D.
`
`form from a professional standpoint, correct?
`
`A.
`
`Q.
`
`No.
`
`And you have never published
`
`on prostacyclins, correct?
`
`A.
`
`Q.
`
`No,
`
`I have not.
`
`And you don't claim to be an
`
`expert in pulmonary hypertension, correct?
`
`A.
`
`Q.
`
`No.
`
`And you haven't developed any
`
`products that have been approved or submitted
`
`for approval
`
`to the FDA for the treatment of a
`
`disease, correct?
`
`A.
`
`Q.
`
`That's correct.
`
`And you have not developed any
`
`drug device combinations that have been
`
`approved or submitted for approval
`
`to the FDA,
`
`
`
`correct?
`
`A.
`
`Q.
`
`That's correct.
`
`And you are not an expert in
`
`the design of nebulizers, correct?
`
`A.
`
`That's correct.
`
`I have an
`
`understanding of nebulizer design, but I
`
`wouldn't
`
`lead that to I
`
`am not in an expert in
`
`the design of.
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 19 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`MAUREEN DONOVAN, Ph.D.
`
`Q.
`
`And you have testified a
`
`number of times in patent cases, correct?
`
`Page 20
`
`
`
`As
`
`Q..
`
`Yes,
`
`I have.
`
`And in all the cases in which
`
`you have testified at trial or in deposition,
`
`they were all on behalf of a generic company,
`
`correct?
`
`A.
`
`I am trying to recall, but I
`
`actually think my very first deposition was on
`
`behalf of the brand owner.
`
`Q.
`
`Was that in Canada?
`
`A.
`
`Q.
`
`Yes, it was.
`
`In all cases in which you have
`
`testified at trial or deposition in the United
`
`States,
`
`they were all on behalf of a generic
`
`company, correct?
`
`A.
`
`Oz
`
`Yes,
`
`they were.
`
`In the course of your
`
`professional career, you have multiple
`
`publications, correct?
`
`A.
`
`Q.
`
`articles?
`
`Yes,
`
`I do.
`
`And are any of those review
`
`Yes.
`A.
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 20 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`
`
`Page 21
`
`MAUREEN DONOVAN, Ph.D.
`
`Q.
`
`A.
`
`Qs
`
`Are any of those abstracts?
`
`Certainly, yeah.
`
`When you publish papers, you
`
`frequently have to perform literature research
`
`and cite to the publication of others, correct?
`
`A.
`
`Yes, that's true.
`
`When you are performing the
`
`research for such endeavors, what steps do you
`
`take to find relevant sources?
`
`A.
`
`Are you speaking -- are we
`
`speaking currently? Are we speaking ever since
`
`I started publishing work?
`
`2004.
`
`Q.
`
`A.
`
`Why don't we think back to
`
`Okay.
`
`So in 2004,
`
`there were
`
`
`
`sort of probably multiple avenues in the area
`
`that I was likely to be publishing in I already
`
`had familiarity with.
`
`So I probably had some
`
`key references. Maybe I had an extensive
`
`collection and was just trying to make sure
`
`that it was completely up to date, but
`
`regardless I certainly start with key
`
`references -- well, let me back up.
`
`Starting with an online
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 21 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 22
`
`MAUREEN DONOVAN, Ph.D.
`
`literature search is certainly a process that
`
`either immediately or initially or as a follow
`
`up to a couple of key references would take
`
`place.
`
`
`
`I would look at databases
`
`that -- that are designed to have or give easy
`
`access to literature, and most of them -- many
`
`of them are linked in my library, and I have --
`
`then I can figure out whether my library owns
`
`that material that I
`
`am interested in or
`
`whether I need to request it as loan material
`
`or whatever.
`
`So I will do several
`
`literature searches.
`
`In 2004 there were
`
`probably -- and even currently -- probably
`
`about three. Maybe in 2004 there were even
`
`four databases that I would typically search if
`
`I were looking for -- it depends on what I was
`
`looking for, but if I was looking for a pretty
`
`extensive cross-section of information, and
`
`then often times if I have a key piece of
`
`literature I have identified or review article
`
`or something else or there is something I want
`
`I will look at the references
`to follow up on,
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 22 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 23
`
`MAUREEN DONOVAN, Ph.D.
`
`that are in that particular piece of
`
`literature.
`
`I will follow up on those.
`
`I
`
`will follow up on the particular key piece by
`
`looking at who has cited that literature and
`
`sort of expand the search in that manner when I
`
`find actual papers or review articles or
`
`something that I think are particularly
`
`valuable that I want to know who else followed
`
`up on those.
`
`
`
`Q.
`
`Okay. And you mentioned that
`
`there were four databases in 2004 that you
`
`might consult.
`
`What databases are those?
`
`A.
`
`I would certainly consult with
`
`PubMed.
`
`I would consult with a database that
`
`was called International Pharmaceutical
`
`Abstracts.
`
`I would consult with what probably
`
`at the time even was the SciFinder database for
`
`the American Chemical Society, and I would look
`
`at the Web of Science database.
`
`Q.
`
`If you were performing a
`
`Similar search in 2006, would there be any
`
`major changes to what you've just described?
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 23 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`
`
`Page 24
`
`MAUREEN DONOVAN, Ph.D.
`
`No.
`
`Is it your opinion that a
`
`A.
`
`Q.
`
`
`
`person of ordinary skill in the art as you have
`
`defined that person in this proceeding in 2006
`
`would go about performing research ina similar
`
`manner?
`
`A.
`
`0:
`
`Yes.
`
`You have indicated that you
`
`have published some abstracts, correct?
`
`A.
`
`Well, abstracts that I have
`
`presented have been published.
`
`QO.
`
`Okay. And what was the
`
`purpose of publishing those abstracts?
`
`A.
`
`Often times the abstracts
`
`that -- the abstracts that are published are
`
`abstracts of presentations that were made at a
`
`national meeting.
`
`The organizations that
`
`sponsor those meetings often times have
`
`associations with particular publications, and
`
`as part of publishing agreements and so forth,
`
`often times the abstracts appear in that
`
`publication post the -- post their
`
`presentation.
`
`As time has gone on,
`
`that --
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 24 of 201
`
`&WwNOF
`oa1oOwo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 25
`
`MAUREEN DONOVAN, Ph.D.
`
`in particular one of the organizations that I
`
`present at most frequently,
`
`they have -- they
`
`now house the abstract -- the abstracts at the
`
`national meetings on their own website.
`
`Q.
`
`And what would be the purpose
`
`of putting the abstracts for the national
`
`meetings on the website?
`
`As
`
`I -- I
`
`am going to suppose
`
`this just because I knew about the
`
`association's agreements with their previous
`
`publishers that it just became a matter of the
`
`next negotiation with the publishers of the
`
`journals that they were associated with that
`
`the association felt that it better served
`
`their members to house the abstracts on their
`
`
`
`website, and that they didn't need to be
`
`associated with any particular journal.
`
`The association had developed
`
`interactions with a number of journals.
`
`I
`
`think a number of them had different
`
`publishers.
`
`So I think it became an issue of
`
`which journal, which publisher, how do you make
`
`this all work.
`
`So given somewhat of the
`
`interdisciplinary nature of the particular
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 25 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 26
`
`MAUREEN DONOVAN, Ph.D.
`
`organization and the meeting and the materials
`
`that are presented there, it became I think
`
`easier for their members to access that
`
`information via the association's website than
`
`it did to select a particular publisher and
`
`journal
`
`to house those.
`
`Q.
`
`In the discussion of how you
`
`might have or a person of ordinary skill in the
`
`art might have gone about performing research
`
`or I guess just going back to that discussion.
`
`If you were searching for works in 2006 about
`
`treating pulmonary hypertension, would you pick
`
`up every issue of a certain periodical for the
`
`last two years and leaf through it because that
`
`periodical happened to deal with, for example,
`
`medicine?
`
`
`
`MR. MATHAS: Object to the form.
`
`BY THE WITNESS:
`
`A.
`
`I'm going to -- well,
`
`I'm
`
`going to answer that as a person who is
`
`interested in -- in pharmaceuticals,
`
`pharmaceutics aspects. Leafing through medical
`
`journals sometimes is a great way to actually
`
`get new ideas for potential new dosage forms or
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 26 of 201
`
`&WwNOF
`oa1oOwo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 27
`
`MAUREEN DONOVAN, Ph.D.
`
`improvements to current dosage forms.
`
`So it's
`
`not out of the question that that might happen.
`
`I don't do it on a regular
`
`basis, and if I am looking for general
`
`information in a particular therapeutic area,
`
`that probably wouldn't be how I would start,
`
`but I am not going to exclude that it wouldn't
`
`be something -- especially I would choose
`
`probably a focused journal in the area to get
`
`an idea of the variety of art.
`
`
`
`The reason is that, you know,
`
`databases are dependent on the words I put into
`
`them in their search, and sometimes I want
`
`to
`
`know what
`
`the vocabulary is that I am not aware
`
`that I could be using in my search terms.
`
`So I
`
`might actually go and look at see what people
`
`are publishing currently or talking about.
`
`BY MS. ASCARRUNZ:
`
`Q.
`
`Okay. Of the four databases
`
`we discussed,
`
`is there one in particular that
`
`you think is the most popular among persons of
`
`ordinary skill in the art as you have defined
`
`that person in 2006?
`
`I guess that's how you go
`A.
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 27 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 28
`
`MAUREEN DONOVAN, Ph.D.
`
`about searching and what you're comfortable
`
`with and what you use is more of an -- not
`
`necessarily an individual preference, but it
`
`often times -- you know, it can be influenced
`
`by what access you have to those materials.
`
`So
`
`it's really difficult for me to speak for all
`
`POSAs on the matter.
`
`0:
`
`Okay.
`
`Sorry to jump around.
`
`I had realized that I forgot to ask some
`
`questions before.
`
`So going back to abstracts
`
`now, you agree with me that abstracts are not
`
`peer reviewed, correct?
`
`A
`
`No,
`
`I don't agree. When I
`
`submit an abstract for presentation, it's
`
`reviewed before it's accepted for presentation.
`
`Q.
`
`Okay. Are abstracts indexed
`
`and searchable?
`
`
`
`A.
`
`Q.
`
`A.
`
`Many times they are, yes.
`
`Is that helpful if they are?
`
`Yes.
`
`It's helpful for people
`
`who weren't able to actually attend the
`
`physical presentation to be able to access, and
`
`I cite abstracts in a number of my
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 28 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 29
`
`MAUREEN DONOVAN, Ph.D.
`
`publications.
`
`So, yes, it's helpful
`
`to have
`
`them indexed and accessible.
`
`Q.
`
`When you cite abstracts in
`
`your publication, how do you go about finding
`
`them?
`
`A.
`
`Many times they show up in my
`
`searches.
`
`If -- again,
`
`they are -- if they are
`
`abstracts that I actually saw the presentation
`
`to, you know,
`
`I where to go look.
`
`I know which
`
`journal supplement the particular abstract is
`
`in based on what meeting I was at and what year
`
`it was during, but otherwise in many cases they
`
`actually are -- those citations show up ina
`
`literature search.
`
`Q.
`
`Okay. Have you ever published
`
`an abstract where preliminary data was
`
`conveyed, but the data did not pan out further
`
`into a full research study?
`
`
`
`A.
`
`Q.
`
`Can you ask that again?
`
`Sure. Let me ask ita
`
`different way. That probably wasn't the most
`
`articulate question.
`
`Have you ever published an
`
`abstract where you presented preliminary data
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext Company
`
`www.veritext.com
`
`UNITED THERAPEUTICS, EX. 2034
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`Page 29 of 201
`
`&WwNOF
`oawowo
`
`10
`
`La
`
`12
`
`LS
`
`14
`
`LS
`
`16
`
`LT
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`ao
`
`

`

`Page 30
`
`MAUREEN DONOVAN, Ph.D.
`
`and then were disappointing in how further
`
`research evolved from that point?
`
`MR. MATHAS: Object to the form.
`
`BY THE WITNESS:
`
`Ax
`
`Well,
`
`I don't know that I am
`
`ever really disappointed in how the research
`
`evolves.
`
`It is what it is.
`
`It may not
`
`actually corroborate the hypothesis I had to
`
`start with, and as a result,
`
`I don't know,
`
`I
`
`may change my hypothesis and change the
`
`approach.
`
`I may decide to discontinue.
`
`I may
`
`identify that I need to do work that requires
`
`me to find a collaborator and that doesn't --
`
`doesn't either work out, or I am not able to
`
`identify a collaborator at the time to move
`
`that on at the right time.
`
`
`
`There's all sorts of things
`
`that would cause an area of research to not
`
`continue to be pursued, and I have a number of
`
`abstracts that the full body of work hasn't
`
`resulted ina -- in a publication.
`
`Some of the
`
`work ends up being resident in my students'
`
`thesis instead, and that's the appropriate
`
`place for that information.
`
`
`800-642-1099
`
`David Feldman Worldwide
`A Veritext

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket